Amylyx Pharmaceuticals Inc (AMLX) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access AMLX Annual Balance Sheets →
This balance sheet overview for Amylyx Pharmaceuticals Inc spans from Mar 31 2025 to Mar 31 2026, showing how the company's assets, liabilities, and equity have evolved across reporting periods.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2026)
(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Assets
Cash & cash equivalent229.14
Marketable Securities, Current SH50.63
Cash & Short-term Investments279.00
Accounts receivable0.00
Prepaid Expense And Other Assets Current5.26
Total Current Assets285.02
Equipment/Property/Plant Net0.21
Other Assets, Noncurrent8.37
Operating Lease Right Of Use Asset4.88
Total Assets293.60
Liabilities
Accounts Payable, Current AC3.53
Accrued Liabilities, Current AC11.28
Other Liabilities, Current1.16
Total Current Liabilities15.97
Total Long-term Debt0.00
Other liabilities, Noncurrent4.48
Operating Lease Liability Current1.16
Operating Lease Liability Noncurrent4.48
Total Liabilities20.44
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock1,065.62
Retained Earnings / Accumulated Deficit-792.71
Other Equity0.24
Common Stockholder's Equity273.16
Total Stockholder's Equity273.16
Liabilities & Stockholder's Equity293.60
4 historic quarters locked

Sign in to unlock the full Amylyx Pharmaceuticals Inc balance sheet history.

About Amylyx Pharmaceuticals Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-336682

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.